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ScienceDirectIn recent years, studies of cis-regulatory mechanisms have
evolved from a predominant focus on promoter regions to the
realization that spatial and temporal gene regulation is
frequently driven by long-range enhancer clusters that operate
within chromosomal compartments. This increased
understanding of genome function, together with the
emergence of technologies that enable whole-genome
sequencing of patients’ DNAs, open the prospect of dissecting
the role of cis-regulatory defects in human disease. In this
review we discuss how recent epigenomic studies have
provided insights into the function of transcriptional enhancers.
We then present examples that illustrate how integrative
genomics can help uncover enhancer sequence variants
underlying Mendelian and common polygenic human disease.
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Introduction
Massive sequencing technologies have demonstrated
an extraordinary power to uncover disease-causing var-
iants in protein-coding sequences. It is now necessary
to ask whether similar technologies can be exploited
to discover defects in the 1 million transcriptional
regulatory sequences that have been unearthed in the
past few years. This challenge, however, is hindered
by our incomplete understanding of the function ofwww.sciencedirect.com transcriptional regulatory elements. This review will
focus on recent advances in understanding the function
of transcriptional enhancers, and present examples
of how integrative genomics can help identify
enhancer defects that underlie Mendelian and polygen-
ic disease.
Clustering of active enhancers
Enhancers were first defined as DNA sequences that
stimulate transcription from a minimal promoter, regard-
less of orientation or relative distance [1]. Subsequent
studies showed that long-range enhancers are pivotal for
spatial and temporal regulation of gene transcription in
metazoan genomes. Most recently it has become possible
to catalogue the entire genomic repertoire of active
enhancers in any cellular population by exploiting dis-
tinctive enhancer features such as: increased accessibility
to enzymes (DNAse-seq, ATAC-seq), or relative nucleo-
some depletion (FAIRE-seq) [2–4]; enrichment of spe-
cific modified histones (H3K27Ac, H3K4me1) [3,5];
occupancy by co-regulatory factors (p300, BRD4, Media-
tor) [6,7]; and finally, RNA transcription from enhancer-
flanking regions [8]. All such features can now be studied
with high-throughput sequencing-based assays, which
has enabled the generation of enhancer maps in numer-
ous cell lines and primary tissues [8,9,10,11].
A recurrent theme that emerged from recent enhancer
maps is that most lineage-specific gene transcription
occurs near clusters of active enhancers. This had been
previously recognized in the form of clusters of evolu-
tionary conserved sequences flanking lineage-specific
regulatory genes [12], or from functional studies of nu-
merous individual loci. However, enhancer maps now
provide an unbiased perspective based on genome-scale
experimental data. Regulatory clusters have thus been
described as clusters of open regulatory elements
(COREs) [2], superenhancers [13], stretch enhancers
[14], or enhancer clusters [11]. One study mapped human
pancreatic islet enhancers, and found that most islet-
enriched genes are associated with three or more
clustered enhancers, which tend to be co-occupied by
multiple islet-specific TFs [11]. Chromatin conformation
capture (3C) assays showed that clustered enhancers form
higher order physical structures and establish physical
interactions with target genes [11]. These enhancer clus-
ters were consistent with earlier studies showing COREs
(open chromatin clusters defined by FAIRE-seq) nearCurrent Opinion in Genetics & Development 2015, 33:71–76
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vation that expression of genes across multiple tissues
correlates with the activity of multiple local enhancers in
the same locus [15]. Another study defined ‘stretch’
enhancers as H3K27Ac-rich chromatin regions >3 kb,
and found them to be frequently located near cell-specific
genes [14]. Another set of studies defined ‘superenhan-
cers’ as extended enhancer regions that show unusually
high occupancy by either Mediator, TFs, or H3K27Ac-
modified nucleosomes [13,16] (for an in-depth com-
mentary on superenhancers see [17]). Superenhancers
have been linked to genes that are central for pluripo-
tency or cell type identity as well as to oncogenes, and
shown to be particularly sensitive to targeting by co-
regulator inhibitors [13,16,18].
Regardless of varying definitions and nomenclatures,
recently described enhancer domains are, in essence, sets
of adjacent active enhancers. This raises the question of
why there is a need for multiple enhancers to create cell-
specific transcription. Possible explanations include re-
dundancy (‘shadow’ enhancers) and combinatorial or
synergistic specificity, although recent genetic studies
provide further explanations. Spitz and colleagues, for
example, used a broad range of mouse genetic tools to
dissect an enhancer cluster regulating Fgf8 [19]. This
showed that the regulatory output of an enhancer cluster
(in this case the cell types in which Fgf8 is expressed) is
not simply a summation of individual enhancer activities,
but is instead dependent on a combined function of
clustered enhancers, or ‘holo-enhancer units’ [19]. On
the other hand, multiple studies indicate that enhancer
clusters form higher-order 3D structures [11,20–22,23],
suggesting that ‘holo-structures’ might be crucial for cell-
specific transcription.
Enhancer function in the context of the 3D
genome
3C studies have established general principles that un-
derlie 3D genome organization, and promise to enlighten
how enhancers interact with their functional targets. Hi-C
sequencing has shown that the genome is packaged at
multiple organizational levels, including so-called topo-
logically associated domains (TADs) [24]. TADs, which
span on average 0.8 Mb, are defined by a high number
of intra-domain 3C interactions and rare interactions
between adjacent domains. A recent study used random
insertions of a reporter that acts as a sensor of endogenous
enhancer activity, and showed that TADs provide a
spatial compartment within which enhancers interact
functionally (and not solely physically) with their target
promoters [25]. Others have demonstrated coordinated
gene regulation within the confines of TADs [26,27].
Increased resolution mapping using 5C or Hi-C libraries
revealed further subdomains within TADs, including
‘loops’ that are bound at their stem by CTCF, as wellCurrent Opinion in Genetics & Development 2015, 33:71–76 as cohesin and mediator-bound cell-specific ‘loops’ that
link enhancers to promoters [28,29]. 4C-seq studies, a 3C
variant that interrogates all genomic sites interacting with
a viewpoint of interest at very high resolution, have shown
that clusters of lineage-specific enhancers establish fre-
quent interactions amongst themselves and with target
gene promoters [11,20–22]. Interestingly, while TAD
boundaries are typically invariant across cell types, they
contain structures that are often cell-specific and dynamic
[28,30].
Looping into promoters is thought to underlie enhancer
function, and this was recently tested by artificial tether-
ing of an enhancer to a promoter, leading to increased
transcriptional activity [31]. It is nevertheless also true
that each enhancer often shows 3C interaction signals
with multiple nearby enhancers and promoters, and each
promoter with multiple enhancers and promoters [32,33].
One theoretical implication of this observation is that if all
such interactions are functional, then sequence variation
in single enhancers could potentially impact multiple
genes. However, while 3C assays most probably do cap-
ture regulatory interactions between enhancers and pro-
moters, it is unclear if all 3C interactions are functional. In
fact, studies have challenged the significance of 3C inter-
actions, and questioned whether other variables apart
from physical proximity affect ligation frequency in 3C
experiments, and whether 3C interaction signals repre-
sent discrete loops [34]. This warrants a need for cross-
link-independent methods for studying 3D structure.
Interestingly, a recent study used high-resolution live
cell imaging to show widespread Sox2-bound clustered
enhancers in ESCs, providing further independent evi-
dence that enhancer clusters form structural units [23].
Diverse approaches are thus becoming available to probe
the impact of enhancer mutations on higher order chro-
matin structures.
Taken together, recent studies provide an initial frame-
work for understanding how long-range enhancers oper-
ate in the context of genome organization. Future studies
that couple 3D interaction experiments with functional
perturbations, including targeted mutations and eQTL
studies, should provide further light on mechanistic and
functional relationships between enhancers and target
genes. This type of knowledge will be vital for under-
standing how enhancer variants could be deleterious in
the context of 3D chromosomal structure, and to identify
the genes that are affected by defective enhancers.
Mendelian regulatory defects
Notable examples of long-range enhancer mutations that
cause monogenic disorders include those regulating SHH
(preaxial polydactyly) [35], SOX9 (Pierre Robin Syn-
drome) [36], and TBX5 (congenital heart disease) [37].
These and other known enhancer mutations were identi-
fied after careful functional characterization of enhancers,www.sciencedirect.com
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of large deletions or rearrangements that were subse-
quently shown to contain enhancers. This approach is
relatively inefficient when compared with the success of
whole-exome sequencing for detection of protein-coding
mutations.
A recent study exemplifies a systematic approach to
discover enhancer mutations (Figure 1). Hattersley and
colleagues carried out whole-genome sequencing and
homozygosity mapping of SNPs in two unrelated consan-
guineous probands with isolated pancreas agenesis and no
causal protein-coding mutations [38]. Integration of this
data with enhancer charts from human embryonic pan-
creatic progenitors revealed homozygous point mutations
in a single unannotated enhancer >25 kb from PTF1A, a
known pancreatic regulatory gene. Subsequent analysis of
12 unrelated families with isolated pancreas agenesis
showed that 10 had rare homozygous mutations in thisFigure 1
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that disrupted functional binding sites of pancreatic de-
velopmental TFs [38].
The analysis of isolated pancreas agenesis has noteworthy
implications. One is that it illustrates how one can prog-
ress from a person’s inventory of >3 million non-coding
variants to the identification of a causal non-coding mu-
tation. It was also an unbiased genome-scale analysis that
showed that mutations that disrupt recognizable cis-reg-
ulatory sequences can be the most common cause of a
discrete phenotype (in this case isolated pancreas agene-
sis). It is also noteworthy that the pancreatic progenitor
enhancer that harbored mutations was inactive in a broad
panel of tissues, which highlights that any search for non-
coding defects needs to focus on disease-relevant epige-
nomic annotations. Finally, it is interesting that despite
that there are multiple pancreatic progenitor enhancers
near PTF1A [4,39], all mutations fell in a single enhancer.Healthy individual
Patient with
pancreas agenesis
G
A
WT enhancer
Mutated enhancer
(b)
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 representation of the PTF1A locus harboring wild-type (A) and
ed box) establishes a physical interaction with the PTF1A promoter
esence of a single-nucleotide enhancer variant in some patients with
es enhancer activity and potentially alters the local chromatin structure
ase mutations that disrupt binding of FOXA2, PDX1 or an unidentified
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show that only some clustered enhancers in Sox2 are
essential in ESCs [40]. This suggests a functional hierar-
chy within enhancer clusters, perhaps due to a hub-like
function of specific enhancers within 3D structures.
The pancreas agenesis studies support future efforts to
integrate whole genome sequencing with regulatory
annotations to discover Mendelian non-coding defects.
Further discoveries of pathogenic enhancer mutations
from screens of natural and engineered variants should
inform computational algorithms that enable prediction
of pathogenic regulatory variants. Despite the limited
amount of data, several approaches have already been
developed to predict which non-coding variants within
regulatory elements are functional. Most have examined
whether variants affect nucleotides in TF-binding motifs,
are under evolutionary selective pressure, or show poly-
morphism in humans [41–43]. Additional factors, such as
the position of variant enhancers in the context of regu-
latory domains, are also probably to affect pathogenicity.
The availability of large numbers of regulatory mutations
should thus facilitate future understanding of Mendelian
and complex non-coding defects.
Common variation in enhancers and human
disease
Most common diseases, including prevalent forms of
cancer, Type 2 diabetes, or late-onset Alzheimer’s dis-
ease, result from environmental factors interacting with
genetic susceptibility variants. Genome-wide association
studies (GWAS) have identified thousands of loci that
affect the susceptibility to common diseases. Many risk
loci do not contain causal protein-coding variants, sug-
gesting a role for regulatory variation [44,45,46]. This
entails major challenges for translating GWAS findings to
molecular insights. Associated haplotype blocks include
many variants, which means that it is necessary to identify
the specific causal regulatory variants at each associated
locus. Even after prioritizing functional variants, there is
no straightforward approach to conclusively establish the
genes that are affected by the variant, and the relevant
biological context. Only when this information is avail-
able is it possible to study how inherited changes in gene
regulation affect cellular pathways that underlie disease.
Recent studies have made considerable progress to address
these challenges. A plethora of studies have now shown
that variants associated with common diseases are enriched
in enhancers, and this has sometimes led to identification of
functional variants [9,11,16,44,45,47,48]. Studies
have further revealed a specific enrichment in enhancer
clusters or superenhancers that are active in cell types that
match a coherent pathophysiological model of the disease
[11,14,16,49]. Two studies, for example, showed that
SNPs associated with Type 2 diabetes and fasting glycemia
levels are enriched in pancreatic islet clustered enhancersCurrent Opinion in Genetics & Development 2015, 33:71–76 and stretch enhancers [11,14]. This showed that islet-
specific regulatory variation is relevant to Type 2 diabetes
pathophysiology, and enabled functional characterization
of discrete risk variants that disrupt TF-binding motifs and
impact the activity of islet enhancers [11]. Another exam-
ple focused on 21 autoimmune disorders, and used dense
genotyping of large patient cohorts to greatly reduce the
number of candidate causal variants per locus [45]. These
SNPs were enriched in non-synonymous protein-coding
variants, but also in enhancer variants, with a notorious
enrichment in dynamically stimulated and clustered T-cell
enhancers [45]. Taken together, recent work has shown
that it is possible to identify disease-associated functional
variants in cell-specific enhancers, which represents a giant
step towards understanding molecular mechanisms of
common diseases.
In addition to identifying functional variants, it is chal-
lenging to define which genes are affected. A study that
analyzed FTO, the major obesity susceptibility locus,
provides a paradigm for how this problem can be tackled
[50]. Risk variants in FTO intronic regions were pre-
sumed to affect FTO, whose mouse KO phenotype causes
reduced body size [51,52]. Unexpectedly, FTO regions
carrying risk variants form 3C interactions with IRX3,
located >400 kb away, and confer enhancer activity in
cellular domains that coincide with IRX3 (rather than
FTO) expression [50]. Furthermore, risk SNPs at FTO
were associated with brain eQTLs that affected expres-
sion of IRX3, but not FTO. Interestingly IRX3 KO mice
show decreased lean body mass [50]. This landmark
study therefore shows that contrary to previous assump-
tions IRX3 is a functional target of regulatory variants that
affect obesity susceptibility.
In summary, recent studies have started to deploy a broad
range of genetic and functional tools that enable untan-
gling the regulatory function of common disease-associ-
ated variants. Clearly, the level of evidence that is needed
to conclusively implicate a specific non-coding variant in
causality remains a challenge. Importantly, most common
diseases are not easily modeled in an organism by intro-
ducing a single regulatory allele. However, as in classic
protein-coding Mendelian diseases, it should be possible
to implicate a genetic variant by combining multiple lines
of evidence, including human genetics (fine mapping,
transethnic studies) and functional studies (allelic expres-
sion, reporter and 3C assays, genome editing). Ultimately,
the goal is not solely to determine which variants are
causal, but to understand the genetic pathways they
regulate and to harness this knowledge to develop more
efficient therapies.
Until very recent times, the fields of gene regulation and
human genetics were largely unlinked. The studies we
have reviewed illustrate how recent advances in these two
fields are rapidly converging to enlighten new geneticwww.sciencedirect.com
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disease.
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